PROCTER & GAMBLE Co
No SEC Form 4 filings for $PG in the last 30 days.
See all $PG insider activity →Procter & Gamble will acquire Thorne, a supplements maker, from private equity for $3.8B in an all-cash deal expected to close by year-end, according to P&G. P&G says Thorne is well-run and priced in line with industry benchmarks. Thorne is expected to generate about $650M in sales this year.
BigGo Finance says Johnson & Johnson (JNJ) raised its quarterly dividend 3.1% to $1.34, extending a 64-year growth streak. It cites Q1 2026 revenue of $24.06B (+9.9% YoY) and raised fiscal 2026 adjusted EPS guidance to $11.45-$11.65. Procter & Gamble (PG) extended a 70-year streak, with $1.0885 quarterly payout and FY27 core EPS guidance of $6.89-$7.11.
UK MHRA approved Eli Lilly’s once-daily oral GLP-1 orforglipron (Foundayo) on 10 Aug 2026 for weight loss and weight maintenance in adults meeting BMI criteria. Bristol Myers Squibb plans a US$2.3bn Houston manufacturing campus within a US$40bn US investment. Novo Nordisk hired Omnicom for US media, ending WPP, and partnered with AWS on AI drug discovery. P&G is expanding Health Care after its US$3.8bn Thorne acquisition.
Over the past 7 days, alphai's AI scored 8 news stories mentioning PG (PROCTER & GAMBLE Co). Coverage has skewed bullish: 5 bullish, 3 neutral, and 0 bearish.
Recent PG coverage spans financial news, mergers & acquisitions and regulation.
The disclosed $3.8B all-cash acquisition is a near-term capital allocation and integration catalyst for P&G, with potential margin and growth read-through to supplements.
The cash-return plan and EPS guidance range reinforce durability, while commodity, energy, and transport headwinds could cap upside.
The Thorne acquisition broadens P&G’s health and wellness exposure and could improve growth mix, but near-term impact depends on integration and realized synergies.
The article frames PG as a high-yield value buy despite weak growth guidance, with a recent $3.8B Thorne acquisition as a growth offset.
Another long-running dividend increase reinforces capital-return credibility, with limited incremental fundamental information.
alphai scores every news story that mentions PG with an AI model for sentiment and relevance, and aggregates insider trades from PROCTER & GAMBLE Co's SEC EDGAR Form 4 filings. Figures refresh continuously.
Procter & Gamble will acquire Thorne, a supplements maker, from private equity for $3.8B in an all-cash deal expected to close by year-end, according to P&G. P&G says Thorne is well-run and priced in line with industry benchmarks. Thorne is expected to generate about $650M in sales this year.
3 min readBigGo Finance says Johnson & Johnson (JNJ) raised its quarterly dividend 3.1% to $1.34, extending a 64-year growth streak. It cites Q1 2026 revenue of $24.06B (+9.9% YoY) and raised fiscal 2026 adjusted EPS guidance to $11.45-$11.65. Procter & Gamble (PG) extended a 70-year streak, with $1.0885 quarterly payout and FY27 core EPS guidance of $6.89-$7.11.
6 min readUK MHRA approved Eli Lilly’s once-daily oral GLP-1 orforglipron (Foundayo) on 10 Aug 2026 for weight loss and weight maintenance in adults meeting BMI criteria. Bristol Myers Squibb plans a US$2.3bn Houston manufacturing campus within a US$40bn US investment. Novo Nordisk hired Omnicom for US media, ending WPP, and partnered with AWS on AI drug discovery. P&G is expanding Health Care after its US$3.8bn Thorne acquisition.
6 min readThe article says Procter & Gamble (NYSE: PG) raised its quarterly dividend to $1.0885 (about $4.354 annually) in April, its 70th consecutive annual increase. It cites July 29 fiscal 2026 results: 3% net sales growth and 2% diluted EPS growth. For fiscal 2027, it guides 1% to 3% organic sales growth and a $7 EPS midpoint. It also notes PG’s $3.8B Thorne acquisition and valuation at 22.2x earnings.
6 min readThe article highlights three Dividend Kings with 60+ years of annual dividend increases: Coca-Cola (KO) raised its quarterly dividend from $0.51 to $0.53 for the 64th consecutive year, citing a recent quarter net revenue up 7%. Procter & Gamble (PG) raised its dividend for a 70-year streak; fiscal 2026 net sales rose 3% with flat earnings. American States Water (AWR) raised its dividend 8.2% for 72 years.
6 min readThe article highlights five “Dividend Kings” that reported Q2 results and maintained long dividend-increase streaks. It cites Warren Buffett’s Berkshire Hathaway KO beating Q2 EPS and raising full-year guidance, AWR Q2 EPS of $1.09 and an 8% dividend hike, FRT Q2 FFO $1.88 and 96% occupancy, and CWT net income $56.5M and dividend growth, among others.
7 min readProcter & Gamble (PG) reported fiscal Q3 2026 results, with Beauty net sales of $3.866 billion, up 11% on a reported basis, and organic sales up 7%, alongside pre-tax earnings of $761 million (+11%). Total net sales were $21.2 billion (+7%), core EPS $1.59 (+3%). P&G also announced a $3.8 billion all-cash acquisition of Thorne HealthTech, expected to close in Q4 2026.
6 min readProcter & Gamble agreed to buy dietary supplement maker Thorne for $3.8 billion, with Thorne reported to exceed $500 million in annual revenue. Kirin Holdings agreed to acquire Jamieson Wellness for C$2.5 billion (US$1.78 billion). Lallemand completed its BIO-CAT Enzymes & Microbials acquisition, effective July 31, 2026, adding U.S. capacity.
6 min readProcter & Gamble (PG) agreed to buy Thorne, a health and wellness brand, from L Catterton for $3.8B in cash, expected to close in Q4 2026. The deal follows an Aug 3 outlook update for fiscal 2027 with core EPS of $6.89 to $7.11, implying 0% to 3% growth, hurt by about $1B in after-tax cost headwinds.
7 min readProcter & Gamble (NYSE:PG) raised its quarterly dividend by 3% to $1.08 per share and reported Q3 FY2026 core EPS of $1.59 (vs $1.5552 expected) and net sales of $21.235 billion (vs $20.517 billion). Management guided FY2026 core EPS to the lower end ($6.83 to $7.09), citing tariff and cost pressures, but said operating cash flow and free cash flow rose in Q3 and FY2025 covered dividends 1.80x.
6 min read
